FIELD: biochemistry.
SUBSTANCE: invention relates to compositions containing a highly concentrated alpha-1-proteinase inhibitor (A1PI) at a concentration of 100 mg/ml to 200 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions may be suitable for subcutaneous administration. These compositions can be used for many therapeutic indications. The invention also relates to a method of preparing the described compositions using single pass tangential flow filtration (SPTFF).
EFFECT: obtaining a composition containing a highly concentrated alpha-1 proteinase inhibitor and a method of its preparation.
14 cl, 5 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| MELATONIN-BASED SOLUTIONS AND POWDERS FOR THEIR PREPARATION | 2012 |
|
RU2646802C2 |
| CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
| MELATONIN-BASED FORMULATIONS FOR PARENTERAL ADMINISTRATION | 2015 |
|
RU2685698C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| COMPOSITIONS CONTAINING ANAKINRA | 2016 |
|
RU2728795C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
